With the spotlight shining brighter than ever on the rising cost of prescription drugs, two health plan executives spoke on Friday about how the trend is putting pressure on their margins and their members.
Pharmacy costs will likely continue to increase next year, with specialty drugs driving much of that cost growth, according to a new survey from Aon Hewitt.
Insurers' efforts to limit rising drug costs are coming to a head in Massachusetts, where state lawmakers have proposed a bill that would create a first-in-the-nation cap on some prices.
As specialty drug costs continue to rise, insurers are working to implement innovative strategies to offset those increased prices, while still helping their members gain access to important treatments.
Medicare and Medicaid will have to spend almost $50 billion to cover just 10 new specialty medications in the next 10 years, according to a new report from Avalere Health.
Specialty drugs continue to take a huge bite out of the pocketbooks of American insurers, employers and individuals, and the cost growth trend is "unsunstainable," according to a new study commissioned by Express Scripts.
Hepatitis C is an expensive health condition that only gets worse if treatment is delayed or postponed--and a new study published in the American Journal of Gastroenterology suggests that a lack of insurance is the "only barrier" facing those unable to obtain treatment.
The healthcare industry continues to evolve in the post-Affordable Care Act market. A new Avalere Health report has summarized four key trends that will impact insurers this year as they update their business models to remain profitable and competitive.
Insurers are adopting more cost-sharing measures, especially coinsurance, to shift the costs of expensive specialty drugs onto consumers who purchase plans sold on health insurance exchanges, according to a new analysis from Avalere Health.
Consumers who enrolled in plans sold on the health insurance exchanges are 59 percent more likely to use pricey specialty drugs, particularly medications that treat HIV and hepatitis C, than people with employer-based coverage, according to a new study from Express Scripts.